中国药业2025，Vol.34Issue(7)：105-108,4.DOI:10.3969/j.issn.1006-4931.2025.07.023
艾米替诺福韦和恩替卡韦治疗慢性乙型肝炎早期临床疗效及安全性比较
Comparison of Early Clinical Efficacy and Safety of Tenofovir Amibufenamide Versus Entecavir in the Treatment of Chronic Hepatitis B
摘要
Abstract
Objective To compare the early efficacy and safety of tenofovir amibufenamide versus entecavir in the treatment of chronic hepatitis B(CHB).Methods A total of 142 CHB patients admitted to the outpatient department of the hospital from November 2021 to May 2023 were selected and divided into the entecavir group(87 cases)and the tenofovir amibufenamide group(55 cases)according to different treatment plans.Based on whether they were negative or positive for hepatitis Be antigen(HBeAg),the patients in the two groups were further divided into the HBeAg(-)subgroups and the HBeAg(+)subgroups.In HBeAg(-)subgroups,there were 40 cases in the entecavir group and 19 cases in the tenofovir amibufenamide group,respectively.The patients in the entecavir group received entecavir,while patients in the tenofovir amibufenamide group received tenofovir amibufenamide.Both groups were treated continuously for 24 weeks.Results After 12 weeks of treatment,the response rates of hepatitis B virus(HBV)DNA in patients with HBeAg(-)and HBeAg(+)in the tenofovir amibufenamide group were significantly higher than those in the entecavir group(89.47%vs.65.00%,41.67%vs.19.15%,P<0.05).After 24 weeks of treatment,the HBV DNA response rates in patients with HBeAg(-)and HBeAg(+)were comparable between the tenofovir amibufenamide group and the entecavir group(89.47%vs.80.00%,58.33%vs.48.94%,P>0.05).After treatment,the HBeAg seroconversion rates in the tenofovir amibufenamide group and entecavir group were 2.78%(1/36)and 8.51%(4/47),respectively.After 12 and 24 weeks of treatment,the recovery rates of alanine aminotransferase were comparable in patients with HBeAg(-)and HBeAg(+)in the tenofovir amibufenamide group and entecavir group(P>0.05).After 12 weeks of treatment,the creatinine levels of patients with HBeAg(-)in the tenofovir amibufenamide group were significantly higher than those in the entecavir group(P<0.05),but both were within the normal range.After 24 weeks of treatment,the creatinine levels in the two groups were comparable(P>0.05).After 12 and 24 weeks of treatment,the liver and kidney function indicators such as total bilirubin,blood urea nitrogen,and uric acid in patients with HBeAg(-)and HBeAg(+)were comparable between the tenofovir amibufenamide group and the entecavir group(P>0.05).The lipid indicators such as total cholesterol,triglycerides,high-density lipoprotein cholesterol,and low-density lipoprotein cholesterol in patients with HBeAg(+)were comparable between the tenofovir amibufenamide group and the entecavir group(P>0.05).The incidence of adverse reactions was comparable between the tenofovir amibufenamide group and the entecavir group(12.73%vs.10.34%,P>0.05).Conclusion Tenofovir amibufenamide has higher early antiviral ability,faster onset of action,and its efficacy and safety are comparable to entecavir.关键词
艾米替诺福韦/恩替卡韦/慢性乙型肝炎/有效性/安全性Key words
tenofovir amibufenamide/entecavir/chronic hepatitis B/efficacy/safety分类
药学引用本文复制引用
马海艳,郝鹏,潘丹,焦亚军,豆妮娜..艾米替诺福韦和恩替卡韦治疗慢性乙型肝炎早期临床疗效及安全性比较[J].中国药业,2025,34(7):105-108,4.基金项目
河北省廊坊市科技支撑计划项目[2023013233]. （）
